Harmony Biosciences Holdings, Inc.

Stage 2 · Advancing · week 16

As of Oct 22, 2026, Harmony Biosciences Holdings is in Stage 2, the uptrend phase, now in week 16 (since Jul 1, 2026). It closed at $36.03, 15.9% below its 52-week high and above its 200-day average, which is rising.

$36.03

-5.95% today

$2.1B · Mid cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is HRMY early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 18w

S2 16w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 5w → S1 3w → S4 11w → S1 8w → S2 3w → S1 1w → S3 6w → S4 10w → S2 18w → S3 9w → S2 9w → S3 2w → S4 8w → S1 7w → S2 9w → S3 1w → S4 9w → S1 2w → S2 9w → S3 3w → S4 9w → S1 6w → S2 16w current

Total tracked: 165 weeks across 23 stage runs.

HRMY among Biotechnology108th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…108	HRMYHarmony Biosciences Holdings, Inc.	Stage 2 · wk 16	81	−11.0%

vs 52W High

-15.9%

$26.27 lo$42.86 hi

15.9% below 52W high, deeper pullback

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 16

1w13w26w

Week 16, proven structure

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

3.9%

200 DMA: $34.68 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

3.26x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-11.0%

+2.0%

+12.3%

YTD

-3.6%

+37.7%

Scan Membership

Breakout Watch

Latest: 2025-01-21

7 appearances in last 60 days. First seen: 2021-09-28.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 16 · Vol 3.26x

2026-10-21S2

Wk 16 · Vol 1.00x

2026-10-20S2

Wk 16 · Vol 0.91x

2026-10-19S2

Wk 16 · Vol 1.15x

2026-10-16S2

Wk 16 · Vol 1.02x

2026-10-15S2

Wk 15 · Vol 0.90x

2026-10-14S2

Wk 15 · Vol 1.07x

2026-10-13S2

Wk 15 · Vol 1.58x

2026-10-12S2

Wk 15 · Vol 1.30x

2026-10-09S2

Wk 15 · Vol 0.55x

2026-10-08S2

Wk 14 · Vol 0.98x

2026-10-07S2

Wk 14 · Vol 0.62x

Moving averages & range

50 DMA

$39.86

200 DMA

$34.68

52W High

$42.86

52W Low

$26.27

5D Low

$36.03

Resistance levels (recent highs)

20d High

$41.26

60d High

$42.86

120d High

$42.86

250d High

$42.86

Next resistance

+14.5%

to 20d High

P/E (TTM)

11.6

Forward 5.1

Earnings Growth (YoY)

+88.2%

Revenue +30.3%

ROE

+20.5%

Profit margin +18.9%

Dividend Yield

0.00%

P/B 2.1

Harmony Biosciences Holdings: quick answers

What stage is Harmony Biosciences Holdings in?

As of Oct 22, 2026, Harmony Biosciences Holdings (HRMY) is in Stage 2, the uptrend phase. It entered Stage 2 on Jul 1, 2026 and is in week 16. What the four stages mean

Is Harmony Biosciences Holdings in an uptrend?

Yes. Harmony Biosciences Holdings is in a Stage 2 uptrend. It trades 3.9% above its 200-day average, which is rising.

How far is Harmony Biosciences Holdings from its 52-week high?

Harmony Biosciences Holdings closed at $36.03 on Oct 22, 2026, 15.9% below its 52-week high of $42.86. Its 52-week low is $26.27.

How has Harmony Biosciences Holdings performed over the past year?

As of Oct 22, 2026, Harmony Biosciences Holdings is up 37.7% over the past year and down 3.6% so far in 2026.

Which sector and industry is Harmony Biosciences Holdings in?

Harmony Biosciences Holdings is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.